Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard

Blood (2019) 133 (11): 1201–1204.

https://doi.org/10.1182/blood-2018-11-886457

Published: 2019

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

Journal Articles

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Peter Martin, MD, Maurizio DiLiberto, PhD, Christopher E Mason, PhD, Scott A Ely, M.D., Jia Ruan, MD, PhD, Richard R. Furman, MD, David Chiron, PhD, Xiangao Huang, PhD, David C Madoff, M.D., Jonathan Navi, Jessica Lewis, PA-C, Alison Bender, PA-C, Amelyn Rodriguez, RN, June Greenberg, RN, Morton Coleman, MD, Selina Chen-Kiang, PhD, John P. Leonard, M.D.

Blood (2013) 122 (21): 4393.

https://doi.org/10.1182/blood.V122.21.4393.4393

Published: 2013

Journal Articles

A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Ruben Niesvizky, MD, Suzanne Lentzsch, MD, PhD, Ashraf Z. Badros, MD, Asher A. Chanan-Khan, MD, Seema B. Singhal, MD, Jeffrey A. Zonder, MD, Ravi Vij, MBBS, MD, Xiangao Huang, PhD, Maurizio DiLiberto, PhD, Rachel Courtney, PhD, M. Naveed Shaik, PhD, Sindy T. Kim, BS, Sophia Randolph, MD, PhD, Scott A Ely, MD, MPH, Selina Chen-Kiang, PhD

Blood (2010) 116 (21): 860.

https://doi.org/10.1182/blood.V116.21.860.860

Published: 2010

Journal Articles

MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells

Tricia Nardiello, BA, Achim A Jungbluth, MD, Anna Mei, BA, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD, Morton Coleman, MD, Roger N Pearse, MD, PhD, David Jayabalan, B.S.M.S, Lloyd J Old, MD, Selina Chen-Kiang, PhD, Hearn J. Cho, MD, PhD

Blood (2010) 116 (21): 785.

https://doi.org/10.1182/blood.V116.21.785.785

Published: 2010

Journal Articles

MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.

Hearn J. Cho, MD, PhD, Anna Mei, Tricia Nardiello, Maurizio DiLiberto, Xiangao Huang, Jennifer E Amengual, MD, Achim Jungbluth, MD, Scott Ely, MD, MPH, Ruben Niesvizky, MD, David S Jayabalan, BSMS, Lloyd Old, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1795.

https://doi.org/10.1182/blood.V114.22.1795.1795

Published: 2009

Journal Articles

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Scott Ely, MD, MPH, David S Jayabalan, Megan C. Manco, Seema Singhal, MD, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, PhD, Isan Chen, MD, Tomer Mark, MD, John P. Leonard, MD, Morton Coleman, MD, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1877.

https://doi.org/10.1182/blood.V114.22.1877.1877

Published: 2009

Journal Articles

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Rentian Feng, PhD, Xiangao Huang, PhD, Les Coulton, PhD, Hendrik De Raeve, MD, Maurizio DiLiberto, PhD, Scott Ely, MD, MPH, Guozhi Xiao, PhD, Min Luo, MD, Eline Menu, PhD, Peter Croucher, MD, G. David Roodman, MD, PhD, Karin Vanderkerken, MD, Selina Chen-Kiang, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 298.

https://doi.org/10.1182/blood.V114.22.298.298

Published: 2009

Journal Articles

Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease.

Hearn J. Cho, MD, PhD, Scott Ely, MD, Wayne R. Austin, AB, Ruben Niesvizky, MD, Roger Pearse, MD, PhD, Morton Coleman, MD, Nina Bhardwaj, MD, PhD, Maurizio DiLiberto, PhD, Selina Chen-Kiang, PhD, Lloyd J. Old, MD, Achim A. Jungbluth, MD

Blood (2006) 108 (11): 3397.

https://doi.org/10.1182/blood.V108.11.3397.3397

Published: 2006

Journal Articles

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Scott Ely, MD, MPH, Maurizio DiLiberto, PhD, Hearn J. Cho, MD, PhD, Udi Y. Gelbshtein, David S. Jayabalan, Sangeeta Aggarwal, MD, Janice L. Gabrilove, MD, Roger N. Pearse, MD, PhD, Karen Pekle, RN, ANPC, Faiza Zafar, RPAC, Zoe Goldberg, MD, John P. Leonard, MD, John J. Wright, MD, Selina Chen-Kiang, PhD, Morton Coleman, MD

Blood (2005) 106 (11): 2574.

https://doi.org/10.1182/blood.V106.11.2574.2574

Published: 2005

Journal Articles

Type I MAGE Proteins: Novel Markers of Proliferation in Multiple Myeloma Progenitor Cells.

Hearn J. Cho, MD, PhD, Otavia Caballero, MD, Achim A. Jungbluth, MD, Maurizio DiLiberto, PhD, Ruben Niesvizky, MD, Lloyd J. Old, MD, Selina Chen-Kiang, PhD

Blood (2005) 106 (11): 5115.

https://doi.org/10.1182/blood.V106.11.5115.5115

Published: 2005

Journal Articles

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

Achim A. Jungbluth, Scott Ely, Maurizio DiLiberto, Ruben Niesvizky, Barbara Williamson, Denise Frosina, Yao-Tseng Chen, Nina Bhardwaj, Selina Chen-Kiang, Lloyd J. Old, Hearn Jay Cho

Blood (2005) 106 (1): 167–174.

https://doi.org/10.1182/blood-2004-12-4931

Published: 2005

NARROW

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Postibrutinib outcomes in patients with mantle cell lymphoma

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells

MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease.

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Type I MAGE Proteins: Novel Markers of Proliferation in Multiple Myeloma Progenitor Cells.

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only